Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs

Arthritis Research

Volumn 2, Issue 5, 2000, Pages 379-385

  Steinmeyer, J ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

COX 2 selective inhibitors; Cyclo oxygenase; Gastrointestinal side effects; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; ISOPROTEIN; KETOPROFEN; LEUKOTRIENE; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PHENAZONE DERIVATIVE; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; ROFECOXIB;

ADENOMATOUS POLYP; AGE; ALCOHOLISM; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; BLOOD CLOTTING DISORDER; BREAST CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HUMAN; INFLAMMATION; KIDNEY DISEASE; MOUSE; NONHUMAN; PAIN; PREGNANCY; PROPHYLAXIS; PROSTAGLANDIN SYNTHESIS; REVIEW; RISK FACTOR; SHEEP; SIDE EFFECT; STOMACH CARCINOMA; STOMACH EROSION; STOMACH LESION; STOMACH PAIN; STOMACH ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; PAIN;

EID: 0034468514     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar116     Document Type: Review

References (64)

1. A depressor substance in seminal fluid
2. Über die spezifische blutdrucksendende Substanz des menschilchen Prostata- und Samenblasensekretes
3. 2
4. Inhibition of prostaglandin biosynthesis as a mechanism of action of aspirin-like drugs
5. How aspirin might work: A pharmacokinetic approach
6. Mechanism of action of antiinflammatory drugs
7. Autoradiographic and biochemical observations on the distribution of non-steroid antiinflammatory drugs
8. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin
9. Biodistribution of mild analgesics
10. Inhibition by anti-inflammatory drugs of prostaglandin production in cultured macrophages
11. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-actamidophenol)
12. 2 synthase (cyclooxygenase) in human monocytes
13. Selective regulation of cellular cyclo-oxygenase by dexamethasone and endotoxin in mice
14. Expression and regulation of COX-2 in synovial tissues of arthritic patients
15. COX-1 und COX-2: Funktionen und pharmakologische Beeinflussung
16. Towards a better aspirin
17. Meloxicam: Influence on arachidonic acid metabolism; part I: In vitro findings
18. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs
19. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
20. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthase
21. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
22. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs)
23. Developmental expression of the cyclooxygenase-1 and cyclooxygenase-2-genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids
24. Selective inhibitors of cyclooxygenase-2: Are they really effective, selective, and GI-safe?
25. Cyclooxygenases 1 and 2
26. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: Implications for Alzheimer's disease
27. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
28. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): An extension of the dietary fat hypothesis of breast cancer
29. Expression of cyclooxygenase-2 in human gastric carcinoma
30. Molecular pathology of cyclooxygenase-2 in neoplasia
31. COX-2 inhibitors. A new class of antiangiogenic agents
32. Gastroduodenal complications of chronic NSAID therapy
33. Nonsteroidal antiinflammatory drugs and the gastro-intestinal tract. The double-edged sword
34. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine
35. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
36. Nonsteroidal antiinflammatory drugs - Differences and similarities
37. Konsequenzen und Kosten der NSA-Gastropathie in Deutschland
38. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System
39. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use
40. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
41. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal
42. Many NSAID users who bleed don't know when to stop
43. Commentary: Bleeding ulcers, interaction between NSAIDs and Helicobacter pylori infection, and nonulcer dyspepsia
44. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?
45. Anit-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
46. A safe non-steroidal anti-inflammatory drug - The search continues
47. Rofecoxib
48. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2-specific inhibitor, with that of ibuprofen on gastroduodenal mucosa of patients with osteoarthritis
49. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
50. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients
51. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2-inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large-scale Evaluation of in osteoarthritis
52. A four-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptoms volunteer
53. COX-2 Hemmer
54. Endoscopic evaluation of the effect of indomethacin capsules and suppositories on the gastric mucosa in rheumatic patients
55. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs
56. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
57. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs
58. Use of concomittant gastro-protective agents, diagnostic testes, and hospitalization among elderly patients who started nonsteroidal antiinflammatory drugs in Quebec
59. Effect of specific COX-2 inhibition in osteoarthritis of the knee: 6 week double blind, placebo controlled pilot study of rofecoxib
60. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
61. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib
62. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis